Dutasteride vs PP405
FDA Approved vs Emerging
compatible Researched · 90% Different mechanisms of action. Dutasteride inhibits both Type I and Type II 5-alpha reductase to block DHT, while PP405 acts on mitochondrial pyruvate carriers in hair follicle stem cells. No overlapping pathways suggest safe co-administration.
Molecular Data
Dutasteride PP405
Weight 528.53 Da ~300-400 Da (exact structure not fully published)
Half-life ~5 weeks (extremely long; active metabolite accumulation over months) Topical application; exact pharmacokinetics not published
Type Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor) Small molecule mitochondrial pyruvate carrier (MPC) inhibitor
Key Benefits
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
PP405
01 Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
02 Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
03 Potentially effective regardless of androgen status, broadening the treatable population
04 Topical application (0.05% gel) limits systemic exposure
05 Phase 2a results demonstrated increased hair count and thickness
06 Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
07 No known sexual or hormonal side effects based on available trial data
Side Effects
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
PP405
Scalp irritation at the application site
Application site reactions (redness, dryness, itching)
Contraindications
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
Known hypersensitivity to PP405 or any component of the gel formulation
Full contraindication profile has not been established (investigational drug)
Pregnant or breastfeeding women should avoid use until safety data is available
Research Evidence
Dutasteride PP405
Status FDA Approved Emerging
References 5 studies 2 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.